
|Videos|May 26, 2017
Improving Radiotherapy Responses in Head and Neck Cancer With Galectin-1
Author(s)Dhanya K. Nambiar, PhD
Dhanya K. Nambiar, PhD, Stanford University, discusses a study exploring galectin-1 in combination with radiation and immune checkpoint therapy in head and neck cancers.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































